Speciality segment to be a key growth driver for Sun Pharma
While these investments currently do not generate commensurate revenues streams, they will augur well for the company in the long term as more speciality products get commercialised.
Source: The Economic Times Healthcare and Biotech News - Category: Pharmaceuticals Source Type: news
More News: Biotechnology | Pharmaceuticals